Clofarabine for Langerhans in Pedi

Langerhans Cell Histiocytosis Clinical Trial

Official title:

Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01796405
• Other study ID #: 12-050
• Status: Withdrawn
• Phase: Phase 2
• First received: February 19, 2013
• Last updated: August 24, 2015

Study information

• Verified date: August 2015
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different diseases. It also means that the FDA has not yet approved clofarabine for your disease.

Clofarabine is a chemotherapy drug that has been used in the treatment of leukemia in children and adults. Information from other research studies suggests that this drug may also be effective in patients with LCH.

The purpose of this study is to estimate the response rates of participants with recurrent LCH to clofarabine within each of two strata: a) low-risk participants with disease reactivation, and b) high-risk participants with risk-organ involvement.

Other purposes are to estimate the progression-free survival after clofarabine treatment, estimate survival of participants with refractory multi-system LCH with risk organ involvement treated with clofarabine and to describe toxicities of clofarabine in participants with LCH.

Description:

If you are willing to participate in this research study you will be asked to undergo some screening test or procedure to find out if you are eligible. Many of these tests and procedures are likely to be part of regular care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. These tests and procedures include the following: a medical history, performance status, blood tests, assessment of disease and pregnancy test. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in this research study. After confirming eligibility you will also have a bone marrow test, electrocardiogram and urinalysis.

You will receive a maximum of 6 cycles of study treatment. Each treatment cycle will last approximately 4 weeks. In each cycle, you will receive the study drug clofarabine daily on the first 5 days (days 1 to 5) and rest for the remaining days. Clofarabine will be administered into the vein (IV) over two hours in the clinic or in the hospital. If you have high-risk disease, the dose of clofarabine will be higher during the first two cycles.

Before the start of each cycle, and at the end of your therapy, you will have a physical exam and you will be asked questions about your general health and specific questions about any problems that you are having and any medications you are taking. You will also have blood and urine tests done to monitor organ functions. You will also undergo an assessment of your disease by x-ray, CT scan, MRI or PET or bone scans, which wil be performed every two cycles and at the end of study treatment.

After the final dose of the study drug there will be a follow up period. Once every three months for the first year, twice yearly for the second and third years, and then annually, you will have a physical exam and be asked questions about your general health. You will also have blood and urine tests performed.

Twice yearly for the first three years, x-ray, CT scan, MRI, PET, and/or bone scans will be repeated if your doctor feels they are necessary.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Have failed first line treatment with prednisone and vinblastine

• Clinical evidence of involvement of hematopoietic system, liver or spleen

• Have failed salvage treatment with cladribine/cytarabine or are not considered to be eligible for such treatment

• Willing to use effective contraception during study and for six months after study treatment

• Adequate marrow and organ function

Exclusion Criteria:

• Pregnant or breastfeeding

• Have received chemotherapy or radiotherapy within 2 weeks of study entry

• Have not recovered from adverse events due to previously administered agents

• Receiving other study agents

• Taking drugs with known renal toxicity

• Use of alternative medicine during study treatment

• Uncontrolled intercurrent illness

• History of a different malignancy except if disease-free for at least five years or within five years for cervical cancer in situ and basal and squamous cell carcinoma of the skin

• Known to be HIV positive on antiretroviral therapy

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Histiocytosis
• Histiocytosis, Langerhans-Cell
• Langerhans Cell Histiocytosis

Intervention

Drug:
• Clofarabine

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Estimated Response Rate	To estimate the response rate of participants with recurrent LCH to clofarabine within each of two strata: a) low-risk participants with disease reactivation; and b) high-risk participants with risk-organ involvement that is refractory to standard treatment.	2 years	No
Secondary	Estimated of Progression Free Survival	To estimate the progression-free survival after clofarabine treatment	2 years	No
Secondary	Estimated survival with risk organ involvement	To estimate survival of participants with refractory multi-system LCH with risk organ involvement treated with clofarabine	2 years	No
Secondary	Chemotherapy feasibility	To determine if clofarabine therapy can be delivered as planned ('chemotherapy feasibility'), and to describe toxicities of clofarabine in participants with LCH.	2 years	No